[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitamin-c\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitamin-c":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,95,125,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637285","phase-2-gingival-hyperpigmentation-treatment-100637285",false,"NCT07595705","Gingival Hyperpigmentation Treatment","Gingival Hyperpigmentation Treatment With Injectable Vitamin C in Conjunction With Glutathione Versus The Conventional Surgical Depigmentation: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nThe selection criteria were done according to Gingival pigmentation index is as follows (Dummett and Bolden)10:\n\n1. Score0:absence of pigmentation\n2. Score1:spotsofbrowntoblackcolororpigments\n3. Score2:browntoblackpatchesbutnotdiffusepigmentation\n4. Score3:diffuse brown to black pigmentation,marginal,and attached.\n\nPatients who have Dummett and Bolden index score 1, 2, or 3 will be included in addition to the following criteria:\n\n1. above 18yrs\n2. systemically free\n3. physiologic gingival hyperpigmentation related to esthetic region\n4. well maintained oral hygiene and willing to undergo minor surgical procedures\n\nExclusion Criteria:\n\n1. systemic diseases associated with pathological hyperpigmentation or improper delayed wound healing (uncontrolled diabetes, autoimmune diseases, etc.)\n2. pregnant and lactating mothers\n3. usage of chlorhexidine or povidone iodine\n4. Local causes (smoking)\n5. periodontal diseases (plaque and non-plaque induced gingivitis or periodontitis)\n6. non compliant patients",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","It is a clinical study conducted to evaluate the effect of vitamin C and Glucathonine injection of pigmented gingival tissue versus surgical removal by scalpel",[27,28,29,30],"Gingival Pigmentation","Depigmentation","Vitamin C","Glutathione",[32,33,34,35],"depigmentation","vit c","glutathione","gingival depigmentation","RECRUITING","2026-05-15",{"date":39,"type":40},"2026-05-19","ACTUAL",{"date":42,"type":40},"2025-08-01",{"date":44,"type":21},"2027-10",{"name":46,"class":47},"Cairo University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":77,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":48},"100592604","dietary-supplements-in-patients-with-coronary-artery-bypass-grafting-for-improving-the-quality-of-healthcare-delivery-100592604","NCT06995586","Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","Inclusion Criteria:\n\n* The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).\n* Signed consent form\n* Ability to adhere to the protocol\n\nExclusion Criteria:\n\n* Any psychiatric, neurological or motor disorder.\n* Hypersensitivity to the components of the supplement.\n* Combined Cardiac Surgery other than CABG and valve or aortic\n* Concurrent participation in other clinical trials.\n* Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and\u002For Omega 3 fatty acids.","40 Years","80 Years",{"count":59,"type":21},108,[61],"NA","Cardiovascular disease (CVD) remains the leading cause of death worldwide. Prevention of CAD by targeting modifiable factors remains a key public health priority. L-Ascorbic Acid (Vitamin C - Vit. C) and Omega 3 fatty acids, Eicosapentaenoic \u002F Docosahexaenoic Acid (EPO\u002FDHA), powerful but also necessary antioxidants for the human body, after observational studies as well as randomized studies seem to have a beneficial effect in the direction of the prevention of CVD with pleiotropic mechanisms. Lignin, a polymer of plant origin that is considered a dietary fiber, has a developed porous structure and can retain exogenous and endogenous toxins, and pathogenic microorganisms. Lactulose considered a prebiotic provides a selective substrate for the metabolism of saccharolytic bacteria with bifidogenic activity and multiple benefits to the host's gut health. Coronary artery bypass grafting (CABG) is an established surgical intervention and treatment of symptoms of myocardial ischemia that improves patient survival Optimal Medical Therapy (OMT) after coronary arterial bypass grafting (CABG) as described in current clinical practice could be made even better by the addition of these beneficial food supplements.\n\nA randomized controlled trial is proposed in an intervention group of 54 post-CABG patients who will be given daily orally in addition to the usual medication, 1000 mg Vitamin C, 840 mg EPO\u002FDHA, 2130 mg Lignin \\& 720 mg Lactulose and a control group of 54 patients (Control Group) in which only usual medication will be administered. The intervention will take place from the 15th postoperative day when CAGB patients are discharged and lasts for 2.5 months (10 weeks) postoperatively. The data will be collected on the 15th, 80-90th postop day in 6 months and 12 months postop and then the statistical analysis of the data will be performed. Considering the number of CABG surgeries performed electively in our clinic, this study is expected to be completed in approximately 2-3 years from the day of initiation.\n\nThe expected knowledge through the expected results such as these will emerge from this study is the potentially beneficial effect of our food supplements administration (intervention), i.e. Vitamin C, EPO\u002FDHA, Lignin \\& Lactulose, on the postoperative course of our patients. Some degree of improvement in the well-being and clinical picture of our patients postoperatively is expected, which will be thoroughly investigated in each phase of the study.",[64,65,66,67,29,68,69,70,71,72,73,74,75,76],"Cardio-pulmonary Bypass","Cardiovascular Diseases","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Supplements","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","CABG","Coronary Artery Bypass Grafting","Prebiotics",[64,65,78,29,70,71,79,68,80,73,74,75,81,82,83,84],"Omega-3 polyunsaturated fatty acids","Omega-3 supplementation","postoperative","postoperative depression","Lignin","adsorbent","prebiotics","NOT_YET_RECRUITING","2026-05-09",{"date":88,"type":40},"2026-05-13",{"date":90,"type":21},"2026-09-01",{"date":92,"type":21},"2028-12-01",{"name":94,"class":47},"Nicosia General Hospital",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":48},"100624827","phase-4-effect-of-vitamin-c-on-length-of-hospital-stay-in-children-with-severe-pneumonia-100624827","NCT07414693","Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia","Efficacy of Vitamin C as an Adjunct to Standard Treatment in Severe Pneumonia in Children Under Five Years of Age: A Clinical Comparison","Inclusion Criteria:\n\n* presenting with severe pneumonia\n* ≤ 48-hours duration\n\nExclusion Criteria:\n\n* Congenital heart disease\n* Children with chronic respiratory illnesses i.e. Asthma, post tuberculosis bronchiectasis and cystic fibrosis\n* Immunosuppressed i.e. primary immune deficiency, malignancy, on steroid therapy","2 Months","59 Months",{"count":105,"type":21},90,[107],"PHASE4","Severe pneumonia is a common and serious illness in young children and often requires hospital admission. This clinical trial aims to find out whether adding vitamin C to standard treatment can reduce the length of hospital stay in children under five years of age admitted with severe pneumonia.\n\nThe main question this study seeks to answer is:\n\nDoes giving vitamin C along with routine treatment help children with severe pneumonia recover faster and go home earlier compared to standard treatment alone?\n\nIn this study, 90 children aged 2 to 59 months who are admitted to the Children's Hospital Multan with severe pneumonia will take part. Severe pneumonia is defined by fast breathing, fever, cough, and one or more danger signs such as difficulty feeding, repeated vomiting, seizures, bluish discoloration of lips, or noisy breathing. Children with chronic lung disease or weakened immunity will not be included.\n\nAfter parental consent, children will be randomly divided into two groups. One group will receive standard treatment only, which includes oxygen therapy and intravenous antibiotics according to hospital protocol. The second group will receive the same standard treatment plus a daily dose of vitamin C. Neither group will receive any experimental or unapproved therapy.\n\nResearchers will closely monitor each child's recovery, including improvement in breathing rate, temperature, oxygen levels, and overall clinical condition. The child will be discharged when the treating physician determines that recovery criteria are met. The number of days spent in the hospital from the start of treatment until discharge will be recorded.\n\nBy comparing the average hospital stay between the two groups, this study aims to determine whether vitamin C is a useful and safe add-on treatment for severe pneumonia in young children. The findings may help improve care and reduce hospital stay for children with severe pneumonia in the future.",[110,29,111],"Pneumonia Childhood","Hospital Stay Time",[113,29,114],"Pneumonia","Hospital Stay","2026-02-12",{"date":117,"type":40},"2026-02-17",{"date":119,"type":40},"2025-08-28",{"date":121,"type":21},"2026-02-27",{"name":123,"class":124},"Children's Hospital and Institute of Child Health, Multan","OTHER_GOV",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":48},"100602248","phase-1-high---dose-vitamin-c-infusion-regimen-based-on-pharmacokinetic-characteristics-for-patients-with-advanced-malignant-solid-tumors-100602248","NCT07121036","High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors","Phase I Clinical Study of a New High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics in Combination With Standard Systemic Therapy for Patients With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* 1\\. Aged 18 - 75 years old, regardless of gender. 2. The subject voluntarily participates, gives full informed consent, signs a written informed consent form, and has good compliance.\n\n  3\\. Histologically or cytologically pathologically diagnosed as advanced or metastatic malignant solid tumor.\n\n  4\\. Physical function status: Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.\n\n  5\\. The patient must have at least one measurable lesion (RECIST 1.1). 6. Sufficient bone marrow, liver, kidney, and heart function were recorded within 7 days before enrollment, and the patient is suitable for routine chemotherapy indicated clinically according to normal care standards.\n\n  7\\. No history of calcium oxalate kidney stones. 8. Expected survival ≥ 12 weeks. 9. Pathological immunohistochemistry requires a negative catalase result. 10. Patients who are undergoing systemic anti - tumor treatment and have disease progression can also enter the protocol, continue the same treatment or start a different chemotherapy regimen without interruption.\n\nExclusion Criteria:\n\n* 1\\. Lack of pathological diagnosis of malignant solid tumor. 2. The patient currently has central nervous system (CNS) metastasis or a history of brain metastasis.\n\n  3\\. Severe gastrointestinal diseases, including active bleeding. 4. Patients with severe or uncontrolled infections, heart or nervous system diseases.\n\n  5\\. Major surgery within 4 weeks or local radiotherapy within 7 days before the administration of the study drug.\n\n  6\\. Dementia or severe mental status changes that prevent obtaining informed consent.\n\n  7\\. Women of childbearing potential must use an acceptable contraceptive method during the study and must undergo a pregnancy test within 7 days after the first chemotherapy.\n\n  8\\. The patient currently has poorly controlled diabetes (fasting blood glucose (FBG) \\> 10 mmol\u002FL).\n\n  9\\. Glucose - 6 - phosphate dehydrogenase (G6PD) deficiency or hereditary spherocytosis.\n\n  10\\. Active pulmonary tuberculosis (TB), patients who are undergoing anti - tuberculosis treatment or have received anti - tuberculosis treatment within 1 year before the first drug administration; patients with positive human immunodeficiency virus (HIV) antibodies; or patients with syphilis infection.\n\n  11\\. Active viral hepatitis. If HBsAg (+) and\u002For HBcAb (+), HBV DNA must be \\\u003C 500 IU\u002FmL, and during the study, the patient must continue the original anti - HBV treatment throughout the process or start using entecavir or tenofovir throughout the process. Patients with positive hepatitis C virus (HCV) ribonucleic acid (RNA) must receive antiviral treatment according to local standard treatment guidelines and have liver function within Grade 1 elevation of NCI - CTCAE Version 5.0.\n\n  12\\. Any abnormal laboratory values or medical conditions that, in the judgment of the investigator, make the patient unfit for the study.","75 Years",{"count":134,"type":21},18,[136],"PHASE1","Vitamin C is an essential water - soluble vitamin for the human body. It plays an important role in various physiological processes as an antioxidant and cofactor for multiple enzymes. Most vertebrates can synthesize vitamin C by themselves, but humans can only obtain it from the diet due to inactivating mutations in the synthesis enzyme gene. The incidence of severe malnutrition in tumor patients is 58.2%, and they often have insufficient intake. Vitamin C can be used for the prevention and treatment of various diseases, including vitamin C deficiency, iron - deficiency anemia, atherosclerosis, and COVID - 19. Its role in anti - tumor treatment was first proposed by Cameron E and Pauling LN in the 1970s. However, it was not verified in a subsequent randomized controlled study at the Mayo Clinic, and this treatment has been controversial ever since. Until subsequent studies found that this difference may be due to different administration routes. Oral administration is limited by absorption, transportation, and metabolism. Even at the maximum tolerated dose, the plasma drug concentration is always \\\u003C 250 μmol\u002FL, while intravenous injection can safely reach a pharmacological plasma concentration of 25 - 30 mmol\u002FL, which is the key to exerting the anti - tumor effect. Therefore, intravenous injection of high - dose vitamin C (HDVC) as an emerging anti - tumor therapy has received renewed attention. A series of clinical studies have confirmed that a dose of 75 - 100 g\u002Fday (1.5 - 2.2 g\u002Fkg) is safe. Most pre - clinical experiments suggest that HDVC can inhibit the development or metastasis of tumors, significantly improve the survival rate of experimental animals, and prolong their survival time. It also has a synergistic or sensitizing effect on chemotherapy, radiotherapy, and targeted therapy. However, the number of clinical trials with positive results is very limited. Only a small number of studies have reported trends of increased disease control and objective response rates. For example, when combined with gemcitabine in the treatment of pancreatic cancer, the overall survival (OS) and progression - free survival (PFS) of patients were prolonged (21.7 months vs. 11.1 months; 13.7 months vs. 4.6 months). Currently, all clinical trials lack standardization and normativity in efficacy detection, and the repeatability of the experiments is poor. This has led to a situation where pre - clinical research shows good results, but clinical translation is very difficult. This may be closely related to the pharmacokinetic characteristics of vitamin C: a short half - life of only 30 minutes, high lability, first - order kinetic elimination, and rapid excretion through the kidneys. It is easily metabolized by the body's antioxidant system (especially reduced glutathione). After the infusion stops, the plasma vitamin C concentration drops rapidly, resulting in insufficient duration of the drug peak concentration or effective concentration to kill tumor cells in the body. Therefore, ensuring sufficient blood drug concentration, prolonging the duration of the effective concentration, and inhibiting the metabolism of antioxidants may improve the therapeutic effect of HDVC. This study attempts to summarize the clinical synergistic strategies of HDVC from existing clinical trials and explore a better HDVC treatment regimen. Based on comprehensive clinical research, we take patients with advanced malignant solid tumors receiving systemic anti - tumor treatment as the research objects. While patients are undergoing systemic anti - tumor treatment, HDVC treatment is combined. Three cohorts are designed: 0.5 g\u002Fkg once a day; 0.5 g\u002Fkg twice a day; 0.75 g\u002Fkg twice a day. All are intravenously dripped continuously for 5 - 7 days during the first cycle of standard systemic anti - tumor therapy, and the blood concentration of vitamin C is detected daily. The main objectives of this study are to study the pharmacokinetic characteristics of different high - dose vitamin C intravenous drip regimens in patients with advanced solid tumors, evaluate whether twice - daily administration can increase the blood concentration of vitamin C, and explore the appropriate regimen for combining high - dose vitamin C intravenous drip with standard systemic therapy in treating patients with advanced malignant solid tumors, providing ideas and a basis for the standardized clinical application of HDVC in the future.",[29],[140,141],"High - dose Vitamin C","cancer","2025-08-06",{"date":144,"type":40},"2025-08-13",{"date":146,"type":40},"2025-03-30",{"date":148,"type":21},"2027-12-31",{"name":150,"class":47},"Zhongnan Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":48},"100402163","phase-3-combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer-100402163","NCT04516681","Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer","Vitamin C Intravenously With Chemotherapy and Adebrelimab in Metastatic Colorectal Cancer With High Expresison Level of GLUT3","Inclusion Criteria:\n\n* Age≥18 years, ≤75 years; Histologically proven peritoneal metastatic adenocarcinoma of colorectal cancer, unresectable metastatic disease; IHC confirmed strong positive GLUT3; measurable disease; Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; Life expectancy of at least 12 weeks; ANC ≥1,500\u002Fmm3; Hemoglobin \\> 8g\u002FdL; platelet ≥ 100,000\u002Fmm3; Laboratory at baseline evaluation for inclusion in the study: creatinine ≤1.5X upper limit \\[if the creatinine is elevated, but ≤1.5X the ULN, a 24 hour creatinine clearance will be obtained, Creatinine clearance \\> 50 mL\u002Fmin (calculated according to Cockroft and Gault)\\]; Transaminase (AST\u002FALT) ≤2.5X upper limit of normal and bilirubin levels ≤1.5X upper limit of normal without liver metastasis; Transaminase (AST\u002FALT) ≤5X upper limit of normal and bilirubin levels ≤1.5X upper limit of normal with liver metastasis; Written informed consent\n\nExclusion Criteria:\n\n* Prior treatment for metastatic disease (adjuvant therapy with fluoropyrimidines +\u002F-oxaliplatin based regimens allowed if stopped 12 months prior to registration on study); Surgery (excluding diagnostic biopsy) or irradiation within 3 weeks prior to study entry; Administration of any investigational drug or agent\u002Fprocedure, i.e. participation in another trial within 4 weeks before beginning treatment; Concurrent chronic systemic immune therapy, chemotherapy, radiation therapy (palliative radiation therapy allowed) or hormone therapy not indicated in the study protocol; Brain metastasis (known or suspected); Pregnant or lactating women; Other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection; Known allergy or any other adverse reaction to any of the drugs or to any related compound; Previous (within 5 years) or concurrent malignancies at other sites with the exception of surgically cured or adequately treated carcinoma in-situ of the cervix and basal cell carcinoma of the skin; Patients with low or moderate expression of GLUT3.",{"count":159,"type":21},400,[161],"PHASE3","Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the efficacy of AA. To date, no previous studies have investigated the combination of therapeutic role of AA and PD-L1 antibody in metastatic colorectal cancer with high expression of GLUT3. This protocol is a randomized controlled study of AA infusions combined with Adebrelimab and FOLFOX +\u002F- bevacizumab versus treatment with FOLFOX +\u002F- bevacizumab alone in metastatic colorectal cancer patients with high expression of GLUT3.",[164,29,165],"Colorectal Cancer","GLUT3","2024-10-22",{"date":168,"type":40},"2024-10-24",{"date":170,"type":21},"2024-12-01",{"date":172,"type":21},"2025-12-01",{"name":174,"class":47},"Fudan University","Vitamin c"]